Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
HTG Molecular Diagnostics Inc (CE) | HTGMQ | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.0025 | 0.0025 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 0.0013 - 0.66 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 0.0025 | USD |
HTG Molecular Diagnostics Inc (CE) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 5.54k | 2.21M | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
HTG Molecular Diagnostics (CE) News
Date | Time | Source | News Article |
---|---|---|---|
7/10/2023 | 05:06 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HTGMQ Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.10 | 0.10 | 0.0025 | 0.0025 | 1,414 | -0.0975 | -97.50% |
3 Months | 0.0015 | 0.10 | 0.0015 | 0.0017809 | 1,539 | 0.001 | 66.67% |
6 Months | 0.0013 | 0.10 | 0.0013 | 0.0037465 | 2,903 | 0.0012 | 92.31% |
1 Year | 0.4411 | 0.66 | 0.0013 | 0.3237821 | 9,588 | -0.4386 | -99.43% |
3 Years | 0.41 | 0.66 | 0.0013 | 0.3556989 | 12,208 | -0.4075 | -99.39% |
5 Years | 0.41 | 0.66 | 0.0013 | 0.3556989 | 12,208 | -0.4075 | -99.39% |
HTG Molecular Diagnostics (CE) Description
HTG's mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes. The company's proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. |